Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Boehringer did not carry out a dedicated clinical trial to show the benefit of Ofev in this less severely affected population, but provided subgroup analyses from two earlier studies – INPULSIS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback